QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

INBX

QT44Inhibrx Biosciences, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
93.05
-1.15-1.22%
OverviewShort InterestFilings
INBXQT44Inhibrx Biosciences, Inc.·NASDAQ
OverviewShort InterestFilings
93.05-1.22%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-2.92
Insider Own-
Shs Outstand14.67M
Perf Week-0.52%
Market Cap1.38BForward P/E-EPS next Y-6.53Insider Trans0.00%Shs Float-Perf Month-15.03%
Enterprise Value1.23BPEG0.10EPS next Q-2.28Inst Own-Short Float-Perf Quarter43.44%
Income-122585681.00P/S1063.10EPS this Y-216.27%Inst Trans-Short Ratio-Perf Half Y14.07%
Sales1.30MP/B-EPS next Y29.29%ROA-70.77%Short Interest-Perf YTD17.78%
Book/sh-1.43P/C-EPS next 5Y-ROE-563.89%52W High155.29 -40.08%Perf Year537.33%
Cash/sh11.04P/FCF-EPS past 3/5Y-ROIC-76.97%52W Low13.97 566.07%Perf 3Y-
Dividend Est.-EV/EBITDA-10.47Sales past 3/5Y-20.63% -40.13%Gross Margin-80.38%Volatility5.35% 5.26%Perf 5Y-
Dividend TTM-EV/Sales943.29EPS Y/Y TTM-107.20%Oper. Margin-9465.46%ATR (14)7.80Perf 10Y-
Dividend Ex-DateMay 30, 2024Quick Ratio6.46Sales Y/Y TTM-Profit Margin-10014.23%RSI (14)43.65Recom2.40
Dividend Gr. 3/5Y-Current Ratio6.46EPS Q/Q23.21%SMA20-3.25%Beta2.54Target Price325.00
Payout0.00%Debt/Eq-0.28Sales Q/Q-SMA50-10.98%Rel Volume1.11Prev Close94.20
Employees156LT Debt/Eq13.13EarningsAug 12SMA20023.96%Avg Volume489.54KPrice93.05
IPO DateJun 04, 2024Option/ShortYes / YesEPS/Sales Surpr.9.28% -Net Debt/EBITDA1.33Volume543,903Change-1.22%
Analyst Ratings
DateActionAnalystRatingTarget
May-15-26ReiteratedStifel Nicolaus$300 → $325
Jan-23-24DowngradeJMP SecuritiesMarket Outperform → Market Perform
Latest News
Jun-15-26
Jun-15-2601:15PM
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional ChondrosarcomaYahoo
09:19AM
Inhibrx Biosciences Says FDA Accepts BLA Seeking Approval Of Ozekibart In Patients With Conventional Chondrosarcoma; PDUFA Goal Date Set For April 14, 2027Benzinga
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue810
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A3322
Gross Profit-22-1-2
Selling, General and Administrative Excl. Other1723128
Research and Development92113204
Other Operating Expense-1-2-3
Operating Income-102-135-331
Interest Expense91213
Unusual Expense
———
Non-Operating Income (Expense)00-2,033
Net Income Before Taxes-111-1401,688
Income Taxes200
Consolidated Net Income-113-1401,688
Net Income From Continuing Operations-113-1401,688
Net Income-113-1401,688
EPS (Recurring)-2.92-9.04116.58
EPS (Basic, Before Extraordinaries)-2.92-9.04116.58
EPS (Diluted)-2.92-9.04116.58
EBITDA-101-1331,703
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio453.621,185.00—
Gross Margin-275.00-100.00—
Operating Margin-1,275.00-13,500.00—
Net Margin-1,412.50-14,000.00—
Shares Outstanding391514
Market Capitalization3,6291,185—
Operating Lease Expense
———
Insider Trading Volume
$97.69$87.90$78.10$68.30$58.51● Close Price0.00M2.82M5.64M8.47M11.29MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
VIKING GLOBAL INVESTORS LP10% OwnerOct 07 '25Sale32.25350,00011,287,50167,018Oct 09 12:00 AM
Kayyem Jon FaizDirectorNov 20 '24Buy14.1918,750266,10269,843Nov 22 12:00 AM
Kayyem Jon FaizDirectorNov 19 '24Buy14.2334,843495,70851,093Nov 22 12:00 AM
Vuori Kristiina MDDirectorOct 03 '24Buy15.006,667100,00520,443Oct 07 12:00 AM
Lappe MarkChief Executive OfficerSep 16 '24Buy17.1313,037223,324705,548Sep 16 12:00 AM
Lappe MarkChief Executive OfficerSep 12 '24Buy15.0526,963405,793692,511Sep 16 12:00 AM
Vuori Kristiina MDDirectorSep 11 '24Buy15.076,45797,30713,776Sep 12 12:00 AM
Vuori Kristiina MDDirectorSep 10 '24Buy15.001792,6857,319Sep 12 12:00 AM
Lappe MarkChief Executive OfficerSep 10 '24Buy15.198,500129,115665,548Sep 10 12:00 AM
Lappe MarkChief Executive OfficerSep 09 '24Buy15.219,500144,495657,048Sep 10 12:00 AM
Lappe MarkChief Executive OfficerSep 06 '24Buy15.2926,000397,540647,548Sep 10 12:00 AM
Eckelman Brendan P.Chief Scientific OfficerMay 28 '24Sale34.30300,00010,290,0001,735,553May 30 12:00 AM
Eckelman Brendan P.Chief Scientific OfficerMay 22 '24Option Exercise28.485,010142,66126,667May 24 12:00 AM
Deck KellyChief Financial OfficerMay 06 '24Option Exercise10.6019,711208,8830May 08 12:00 AM
Deck KellyChief Financial OfficerMar 26 '24Option Exercise28.322,89682,00621,250Mar 28 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR